单克隆抗体
药效学
中止
药代动力学
医学
肿瘤科
抗体
药理学
抗体疗法
单克隆
内科学
免疫学
作者
Olivier Mir,Sophie Broutin,Aude Desnoyer,J Delahousse,Nathalie Chaput,Angélo Paci
标识
DOI:10.1016/j.ejca.2020.01.004
摘要
Monoclonal antibodies in oncology, used as targeted molecular therapy, linked to cytotoxic compound or directed against immune checkpoints, feature complex PKs essentially determined by their physicochemical characteristics. The increasing number of studies shows the existence of Pharmacokinetics/Pharmacodynamic (PK/PD) relationships for many of them. Although more studies, especially conducted in early clinical phases, are needed, existing studies highlight the need to integrate PK data for monoclonal antibodies in all phases of their development and the therapeutic management of patients with cancer. The current challenge is to identify non-responders as soon as possible. The use of monoclonal antibody dosage to determine the patient's PK profile and, as a result, the disease activity profile could therefore be an early predictive marker to help physicians optimise the strategy to be pursued, including dose adjustment, prolongation of the dose interval or even discontinuation of treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI